Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965435 | 0.99 | CNR1 (0.49) | CNR1CNR2KMT2ANPSR1MEN1 | |
| SCHEMBL9965398 | 0.87 | SMN1; SMN2 (0.50) | CNR1CNR2KMT2AMEN1LMNA | |
| SCHEMBL9965400 | 0.87 | KMT2A (0.51) | CNR1CNR2KMT2ANPSR1MEN1 | |
| SCHEMBL5073514 | 0.86 | CHRM1 (0.46) | KMT2ANPSR1MEN1LMNAMAPT | |
| SCHEMBL9965441 | 0.86 | SMN1; SMN2 (0.48) | CNR1CNR2KMT2AMEN1MAPT | |
| SCHEMBL9965414 | 0.85 | KMT2A (0.49) | CNR1CNR2KMT2ANPSR1MEN1 | |
| SCHEMBL642098 | 0.85 | NPSR1 (0.52) | CNR1CNR2KMT2ANPSR1MEN1 | |
| SCHEMBL642239 | 0.84 | CNR1 (0.49) | CNR1CNR2KMT2ANPSR1MEN1 | |
| SCHEMBL9965470 | 0.84 | NPSR1 (0.49) | KMT2ANPSR1MEN1LMNAMAPT | |
| SCHEMBL641134 | 0.84 | CNR1 (0.49) | CNR1CNR2KMT2ANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | CNR1 23/4885CNR2 33/4885KMT2A 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.